Description
Less than 15 years have passed since the first iPhone was introduced. It started a revolution in the world of cell phones. For most, they are a necessity to everyday life. The features have continued to improve throughout the years. How is it that the technology for something so basic has grown exponentially, but in the world of CRT our technology seems to be stunted in many ways? Funding seems to always to be the culprit. Not knowing if something will be reimbursed and for how much places a big wall in front of innovation. In this course we’ll discuss how clinicians, ATPs, manufacturers, and providers can help overcome this issue. There are many factors that involve everyone; it’s time to learn.
Claudia Amortegui is the president of The Orion Group, a consulting company specializing in the reimbursement of DME with a focus on complex rehab technology. She has been consulting for over 20 years, but first worked on all sides of the industry: with a Medicare contractor, a manufacturer, and a provider. As a consultant, Claudia has worked with local and national DME providers in improving their overall Medicare business; she also works directly with equipment manufacturers, clinical referrals and funding sources assisting them with reimbursement issues that affect their role in the overall process. Claudia presents at various industry conferences and her articles are regularly published.
Learning Outcomes:
Participants will be able to describe at least 3 key elements in the funding of new CRT technology.
Participants will be able to identify the language needed when justifying new technology in order to obtain proper reimbursement.
Participants will be able to compare documentation to understand what would be considered for coverage vs. likely denials.